A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer

Castrate-resistant prostate cancer (CRPC) remains incurable due to the lack of effective therapies. Several tyrosine kinases have been implicated in the development and growth of CRPC, as such targeting these kinases may offer an alternative therapeutic strategy. We established the combination of tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Archibald, Monica, Pritchard, Tara, Nehoff, Hayley, Rosengren, Rhonda J, Greish, Khaled, Taurin, Sebastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712974/
https://www.ncbi.nlm.nih.gov/pubmed/26811677
http://dx.doi.org/10.2147/IJN.S97286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712974/
https://www.ncbi.nlm.nih.gov/pubmed/26811677
http://dx.doi.org/10.2147/IJN.S97286

Ejemplares similares